IntelGenx to Present at Roth Capital Partners 25th Annual Growth Stock Conference

262 views

Published on

Saint Laurent, Quebec--(Newsfile Corp. - March 18, 2013) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) (the "Company") today announced that it will be presenting at the Roth Capital Partners 25th Annual Growth Stock Conference at the Ritz-Carlton Hotel in Dana Point, California.

The presentation at the Roth conference is scheduled for 11:00 am PDT (2:00 pm EDT) on Wednesday March 20, 2013. The presentation will be webcast, and a recording of the webcast will be available on IntelGenx' website shortly thereafter.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
262
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

IntelGenx to Present at Roth Capital Partners 25th Annual Growth Stock Conference

  1. 1. IntelGenx To Present At Roth Capital Partners 25th Annual Growth StockConferenceSAINT LAURENT, QUEBEC, March 18, 2013 - IntelGenx Corp. (TSX-V: IGX) (OTCQX:IGXT) (the “Company”) today announced that it will be presenting at the Roth Capital Partners25th Annual Growth Stock Conference at the Ritz-Carlton Hotel in Dana Point, California.The presentation at the Roth conference is scheduled for 11:00 am PDT (2:00 pm EDT) onWednesday March 20, 2013. The presentation will be webcast, and a recording of the webcastwill be available on IntelGenx’ website shortly thereafter.About IntelGenx:IntelGenx is a drug delivery company focused on the development of oral controlled-releaseproducts as well as novel rapidly disintegrating delivery systems. IntelGenx uses its uniquemultiple layer delivery system to provide zero-order release of active drugs in the gastrointestinaltract. IntelGenx has also developed novel delivery technologies for the rapid delivery ofpharmaceutically active substances in the oral cavity based on its experience with rapidlydisintegrating films. IntelGenx development pipeline includes products for the treatment ofsevere depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine,insomnia, idiopathic pulmonary fibrosis, allergies and pain management. More information isavailable about the company at www.intelgenx.com.Forward Looking Statements:This document may contain forward-looking information about IntelGenx operating results andbusiness prospects that involve substantial risks and uncertainties. Statements that are not purelyhistorical are forward-looking statements within the meaning of Section 21E of the SecuritiesExchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended.These statements include, but are not limited to, statements about IntelGenx plans, objectives,expectations, strategies, intentions or other characterizations of future events or circumstancesand are generally identified by the words "may," "expects," "anticipates," "intends," "plans,""believes," "seeks," "estimates," "could," "would," and similar expressions. All forward lookingstatements are expressly qualified in their entirety by this cautionary statement. Because theseforward-looking statements are subject to a number of risks and uncertainties, IntelGenx actualresults could differ materially from those expressed or implied by these forward lookingstatements. Factors that could cause or contribute to such differences include, but are not limitedto, those discussed under the heading "Risk Factors" in IntelGenx annual report on Form 10-Kfor the fiscal year ended December 31, 2011, filed with the United States Securities andExchange Commission and available at www.sec.gov, and also filed with Canadian securities

×